Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemiaReport as inadecuate

Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia - Download this document for free, or read online. Document in PDF available to download.

Journal of Hematology and Oncology

, 9:64

First Online: 03 August 2016Received: 01 June 2016Accepted: 27 July 2016DOI: 10.1186-s13045-016-0294-x

Cite this article as: Mahmud, H., Kornblau, S.M., ter Elst, A. et al. J Hematol Oncol 2016 9: 64. doi:10.1186-s13045-016-0294-x


The epidermal growth factor receptor EGFR inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia AML in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in ~15 % of AML patients. This suggests that future studies need to be conducted with a subset of AML patients characterized by high EGFR expression.

KeywordsEGFR AML RPPA Kinome Leukemia Electronic supplementary materialThe online version of this article doi:10.1186-s13045-016-0294-x contains supplementary material, which is available to authorized users.

Download fulltext PDF


Source: https://link.springer.com/


Related documents